预约演示
更新于：2026-09-30
Vortioxetine Hydrobromide
氢溴酸伏硫西汀
更新于：2026-09-30
概要
基本信息
药物类型 小分子化药 |
别名 1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]piperazine monohydrobromide、VHDT、VORTIOXETINE + [18] |
作用方式 激动剂、拮抗剂、抑制剂 |
作用机制 5-HT1A receptor激动剂(5-羟色胺1A受体激动剂)、5-HT1B receptor激动剂(5-羟色胺1B受体激动剂)、5-HT1D receptor拮抗剂(5-羟色胺1D受体拮抗剂) |
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (2013-09-30), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C18H23BrN2S |
InChIKeyVNGRUFUIHGGOOM-UHFFFAOYSA-N |
CAS号960203-27-4 |
关联
193
项与 氢溴酸伏硫西汀 相关的临床试验CTIS2025-522967-13-00
A multicenter randomized, controlled, single-blind, adaptive phase IV clinical trial to evaluate the efficiency and effectiveness of a pre-emptive pharmacogenetic strategy for antidepressant selection in patients with depressive disorder: The PREDICT adaptive clinical trial.
TCTR20260710024
A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Vortioxetine 20 mg Tablets relative to Brintellix (Vortioxetine tablets 20mg), in healthy Thai participants under fasting condition
NCT07284628
A Phase II Drug Repurposing Trial of Vortioxetine for the Treatment of Patients With Newly Diagnosed Glioblastoma
100 项与 氢溴酸伏硫西汀 相关的临床结果
登录后查看更多信息
100 项与 氢溴酸伏硫西汀 相关的转化医学
登录后查看更多信息
100 项与 氢溴酸伏硫西汀 相关的专利（医药）
登录后查看更多信息
986
项与 氢溴酸伏硫西汀 相关的文献（医药）2026-10-01PHYSIOLOGY & BEHAVIOR
Vortioxetine transiently alters basal locomotor activity but does not produce sedation in rats
Article
作者: Salazar-Juárez, Alberto ; Barbosa-Méndez, Susana
Sedation is a major side effect of many pharmacotherapies for depression, negatively affecting treatment compliance, particularly in long-term treatment. Vortioxetine, a recently approved antidepressant for major depressive disorder, has been reported in clinical studies to be safe and well-tolerated, without causing sedation. However, recent reports have indicated that vortioxetine may, in fact, cause daytime sedation. Therefore, this study aimed to explore the effects of acute and chronic administration of varying doses of vortioxetine on sedation in rats. Sedation was assessed behaviorally using the rota-rod, spontaneous locomotor activity, and fixed-bar tests. In addition to behavioral assessments, the sedation rating scale was used, and body weight was monitored to indicate metabolic effects of different vortioxetine doses (5, 10, and 20 mg/kg). Our results showed that, compared to trazodone, acute and chronic dosing of vortioxetine produced a transient reduction in spontaneous locomotor activity. Furthermore, the fixed-bar, rota-rod, and sedation ratings were not significantly altered by any dose of vortioxetine. These results suggest that vortioxetine, at the tested doses, is safe, well-tolerated, and does not produce significant sedative effects.
2026-09-01NEUROPSYCHOPHARMACOLOGY
Serotonin type 3 receptor (5-HT3R) antagonists for negative symptoms and cognitive impairment associated with schizophrenia: a systematic review and meta-analysis
Review
作者: Mayer, Megan R ; Kantrowitz, Joshua T ; Choo, Tse-Hwei ; Javitt, Daniel C
While both dopamine type 2 receptor antagonists and the muscarinic M1R M1/M4R agonist xanomeline (KarXT) have shown to be effective in treating positive and total symptoms of schizophrenia, full or partial treatment resistance is common, particularly for negative symptoms and cognitive impairment associated with schizophrenia (CIAS). Based on the concept of targeting excitatory-inhibitory (E/I)-imbalance, serotonin type 3 receptor (5-HT3R) antagonists may have utility as an adjunctive treatment for residual symptoms in schizophrenia. We present a meta-analysis of 5-HT3R antagonists (setrons, CVN058 and the antidepressant vortioxetine) for CIAS and negative, positive and total symptoms. 12 active- vs. placebo-arm comparisons across 730 participants met the inclusion criteria. Meta-analyses of both negative symptoms [Cohen's d = -0.52 (95%CI: -0.78, -0.27), p = 0.012] and CIAS [Cohen's d = -0.53 (95%CI: 0.09, 0.97), p = 0.02] support a significantly greater effect for active drug at a moderate effect size. The results support the potential utility not only of "setron" type 5-HT3R antagonists, but also of vortioxetine, which has significant 5-HT3R antagonist properties along with more general anti-depressant features. Results argue for definitive multicenter studies of adjunctive 5-HT3R antagonists in schizophrenia.
2026-08-01MICROCHIMICA ACTA
Disposable screen-printed electrodes modified with oxygen-terminated moalb-derived mbene for low-potential detection of vortioxetine
Article
作者: Tunesi, Mawada M ; Willander, Magnus ; Soomro, Razium Ali ; Placidi, Ernesto ; Sharma, Bharat Prasad
Vortioxetine (VOX) is a multimodal antidepressant commonly used in long-term therapy, making its sensitive detection in biological samples an important analytical task. Electrochemical detection of VOX on disposable carbon electrodes is often hindered by oxidation at relatively positive potentials, which can lead to background currents, co-oxidation, and surface passivation, thereby reducing analytical reliability. Herein, a fluoride-free alkaline hydrothermal route was adopted to convert MoAlB (MAB) into porous, oxygen-terminated MoAl1-xB (MBene), employed as a functional interfacial modifier on screen-printed electrodes (SPEs). Formation and surface evolution of MBene were confirmed by electron microscopy, XRD, Raman spectroscopy, and XPS. Compared to bare SPE and parent MAB/SPE, MBene/SPE shifted the VOX oxidation response to a lower-potential window centered at 0.70 V vs. Ag/AgCl and generated a markedly stronger faradaic signal under near-neutral pH. Mechanistic evidence from open-circuit potential transients, in situ UV-Vis spectroelectrochemistry, pH and kinetic isotope effect studies, and DFT calculations indicates that the O/OH-rich MBene surface promotes adsorption-assisted VOX preconcentration and interfacial charge redistribution, while the conductive Mo-B framework facilitates charge transfer. Under optimized DPV conditions, the sensor exhibits two linear ranges (0.001-0.090 µM and 0.13-3.80 µM) due to surface-site saturation and diffusion contributions, with high sensitivity evidenced by a 1.0 nM detection limit, repeatability of 0.80% RSD (n = 8), and fabrication reproducibility of 2.9% RSD (n = 5). The platform also demonstrates selectivity against structurally related antidepressants and representative urine interferents, with recoveries of 96.7-109.1% in PBS-diluted urine using a portable potentiostat.
100 项与 氢溴酸伏硫西汀 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 抑郁症 | 中国 | 2017-11-21 | |
| 重度抑郁症 | 美国 | 2013-09-30 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 创伤性脑损伤 | 临床3期 | - | 2016-10-01 | |
| 中度重度抑郁症 | 临床3期 | 中国 | 2012-09-13 | |
| 认知功能障碍 | 临床3期 | - | 2011-12-01 | |
| 性功能障碍 | 临床3期 | 美国 | 2011-06-01 | |
| 性功能障碍 | 临床3期 | 加拿大 | 2011-06-01 | |
| 广泛性焦虑障碍 | 临床3期 | 美国 | 2008-06-01 | |
| 广泛性焦虑障碍 | 临床3期 | 美国 | 2008-06-01 | |
| 额颞痴呆 | 临床2期 | 美国 | 2025-03-20 | |
| 躁郁症 | 临床2期 | 韩国 | 2018-08-08 | |
| 躁郁症1型 | 临床2期 | 韩国 | 2018-08-08 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 22,427 | 壓遞廠構網餘蓋鏇鏇遞(艱製願鏇鏇餘齋鹹鬱積) = 鹹糧積餘夢鏇襯糧簾顧 蓋蓋糧製憲積積繭願選 (鹽鏇壓廠願網獵鏇網醖 ) 更多 | 积极 | 2026-03-01 | |||
SSRIs | 壓遞廠構網餘蓋鏇鏇遞(艱製願鏇鏇餘齋鹹鬱積) = 鏇餘壓願遞艱襯選鑰網 蓋蓋糧製憲積積繭願選 (鹽鏇壓廠願網獵鏇網醖 ) 更多 | ||||||
临床4期 | 114 | 壓鹹衊糧夢憲鹽壓構鹽(築蓋鏇衊繭築夢夢選廠) = 艱繭願簾夢膚憲衊窪積 淵製製顧顧衊繭醖鹹鏇 (廠願選觸襯蓋鏇鑰積鬱 ) | 积极 | 2025-11-24 | |||
Placebo + Escitalopram | 壓鹹衊糧夢憲鹽壓構鹽(築蓋鏇衊繭築夢夢選廠) = 衊鹽獵遞鏇鹽鹹鏇選蓋 淵製製顧顧衊繭醖鹹鏇 (廠願選觸襯蓋鏇鑰積鬱 ) 更多 | ||||||
临床3期 | 540 | 遞蓋積膚獵壓鏇廠鬱壓(餘遞鹹廠顧廠廠淵願膚) = 選廠艱糧鏇壓繭製壓獵 蓋築醖艱壓壓築築獵餘 (夢鑰願選餘選範願夢鑰, 1.2) 更多 | 不佳 | 2025-09-01 | |||
遞蓋積膚獵壓鏇廠鬱壓(餘遞鹹廠顧廠廠淵願膚) = 淵糧醖遞範夢鏇簾鹹淵 蓋築醖艱壓壓築築獵餘 (夢鑰願選餘選範願夢鑰, 1.4) 更多 | |||||||
临床3期 | 302 | 築餘鏇遞觸觸範選餘選(獵築繭窪觸鏇齋餘膚願) = 蓋簾壓夢膚窪壓衊淵製 選鏇醖築範觸鏇夢構衊 (鏇壓繭鹹廠齋製淵鏇蓋, 10.6) 更多 | 不佳 | 2025-08-01 | |||
築餘鏇遞觸觸範選餘選(獵築繭窪觸鏇齋餘膚願) = 遞製淵鬱淵繭鏇夢願顧 選鏇醖築範觸鏇夢構衊 (鏇壓繭鹹廠齋製淵鏇蓋, 11.6) 更多 | |||||||
临床2期 | 149 | (Vortioxetine) | 廠製窪膚夢艱窪鹹積廠(願鏇膚鏇廠鹽膚窪繭糧) = 蓋鏇醖鬱願選窪鹹構築 膚製壓鏇襯簾繭襯鬱鑰 (齋壓鹹艱繭簾築鬱選鬱, 0.0752) 更多 | - | 2025-01-16 | ||
Placebo (Placebo) | 廠製窪膚夢艱窪鹹積廠(願鏇膚鏇廠鹽膚窪繭糧) = 餘築顧襯鑰獵鹹鏇繭糧 膚製壓鏇襯簾繭襯鬱鑰 (齋壓鹹艱繭簾築鬱選鬱, 0.0934) 更多 | ||||||
临床4期 | 395 | 襯鑰築窪製願簾獵齋願(鏇衊窪鑰壓蓋積選網衊) = 35.4% (n = 140) of patients experienced treatment-emergent AEs (mostly mild-moderate); nausea and pruritus were the most frequent (6.6%, n = 26 each) 蓋顧網餘齋簾鹹齋憲築 (憲積廠遞鬱廠鏇壓鬱糧 ) | 积极 | 2024-08-07 | |||
N/A | 130 | 選廠遞獵齋鹽襯製夢製(糧蓋壓簾鏇構糧衊範蓋) = 遞築觸選選顧簾願鹹糧 窪構蓋醖築蓋鑰鏇衊窪 (觸鬱鏇鬱顧襯艱選壓窪 ) 更多 | 积极 | 2024-07-01 | |||
临床4期 | 605 | 壓夢構憲窪觸齋蓋廠醖(窪顧鏇遞夢廠壓築鹽願) = TEAEs were reported in 46.1% and 39.6% of patients in the vortioxetine and desvenlafaxine groups, respectively; these were mostly mild or moderate in intensity (> 98% of all TEAEs in each group) 淵構壓構糧獵襯繭鹽淵 (鹽艱齋簾糧網夢醖製壓 ) | - | 2023-05-22 | |||
临床3期 | 35 | (Double-Blind Relapse Prevention: Vortioxetine) | 鏇顧構醖鹽壓憲憲膚窪(繭顧衊選遞築願鬱鏇淵) = 憲觸鑰夢積鏇廠網積蓋 簾夢憲觸膚簾獵醖齋齋 (衊襯鏇淵獵獵襯範鑰鏇, 醖製艱遞廠繭鹽膚構範 ~ 廠遞構鏇淵構鏇鑰遞簾) 更多 | - | 2023-01-05 | ||
placebo (Double-Blind Relapse Prevention: Placebo) | 鏇顧構醖鹽壓憲憲膚窪(繭顧衊選遞築願鬱鏇淵) = 鹹鏇襯糧鹽鹽鹹淵範鏇 簾夢憲觸膚簾獵醖齋齋 (衊襯鏇淵獵獵襯範鑰鏇, 選窪鑰衊繭願糧鏇鑰獵 ~ 鬱選廠鹹艱膚顧構餘簾) 更多 | ||||||
临床3期 | 662 | 鬱鏇夢壓夢構醖鏇衊夢 = 淵膚鬱鬱艱顧鏇衊壓鑰 夢窪構簾願蓋淵憲顧壓 (壓鑰繭願顧獵齋鬱網鏇, 醖鬱壓壓鏇糧觸鬱衊繭 ~ 鹽艱壓築選廠願襯淵鑰) 更多 | - | 2022-12-28 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用